Melanotan II Injectable Recalled for Manufacturing Sterility Defect
Melanotan II injection (35 vials) is being recalled nationwide due to manufacturing deviations that could compromise product sterility. Patients should not use affected lots and should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a risk-of-harm sterile injectable drug with manufacturing deviations that could compromise sterility. No illnesses have been reported, meeting the criteria for High severity per the rubric.
Plain-English summary
Melanotan II 1 mg/mL injectable medication has been recalled by the U.S. Food and Drug Administration. The recall involves 35 vials manufactured by North American Custom Laboratories, LLC (operating as FarmaKeio Superior Custom Compounding) and distributed nationwide. The affected lot numbers are 32610 (use-by date: 4/4/2022) and 35126 (use-by date: 6/7/2022).
The recall was initiated due to deviations from Current Good Manufacturing Practices (CGMP) that undermine confidence in the sterility of the product. As Melanotan II is an injectable medication intended for sterile administration, these manufacturing defects create a potential safety concern.
Patients or healthcare providers who have this medication should not use the affected lot numbers. Contact your healthcare provider or the FDA if you have questions about whether you have received this recalled product.
The recalled product
- Product
- Melanotan II 1 mg/mL (10 mL) Injection, 10mL vials, Rx only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081 USA
- Manufacturer
- North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
- Category
- Drug
- Hazard
- sterility-assurance
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 32610 BUD: 4/4/2022
- 35126 BUD: 6/7/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27